Clinical Trial Update: Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause [Phase 2]

View source ↗

Summary

Phase 2 study evaluating eight-week efficacy and safety of Brisdelle (paroxetine mesylate) for vasomotor symptoms in menopause; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Flashes
• Menopause
• Vasomotor Symptoms

Drugs mentioned

• Brisdelle (paroxetine mesylate)

Snippet

Sponsor: Noven Therapeutics | Conditions: Hot Flashes | Phase 2 | Status: COMPLETED | Results posted: 2014-03-12